DHODH

ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat

Retrieved on: 
Thursday, February 29, 2024
SAN, EPO, Composition, Alopecia areata, Patent, Patient, International Examiner, DHODH, ASLN, European Patent Convention, Pharmaceutical industry

Farudodstat is a potent, oral dihydroorotate dehydrogenase (DHODH) inhibitor with the potential to be a first-in-class treatment option for alopecia areata (AA).

Key Points: 
  • Farudodstat is a potent, oral dihydroorotate dehydrogenase (DHODH) inhibitor with the potential to be a first-in-class treatment option for alopecia areata (AA).
  • ASLAN is currently conducting a Phase 2a proof-of-concept trial in AA (the “FAST-AA Study”) and an interim readout from the study is expected mid-2024.
  • “We are very pleased to have received a positive preliminary opinion from the EPO on the Composition of Matter patent application for farudodstat, and recognition that all of our claims were novel and inventive.
  • If granted in the national stages, the new patent will extend the patent protection on farudodstat until at least 2043.

EQS-News: Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Janus, Biotechnology, Conference, MRI, Serum, Histology, Regeneration, PMS, Multiple sclerosis, Woman, Disease, Calcium, Clinical trial, Investment, AFL, SIRT6, Medicinal chemistry, Ulcerative colitis, Biomarker, Journal of Medicinal Chemistry, DHODH, Patient, Journal, RMS, Magnetic resonance imaging, Pharmaceutical industry

“With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.

Key Points: 
  • “With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.
  • A more thorough review of recent events and upcoming milestones follows:
    Announced a three-tranche private placement of up to $240 million with participation from select new and existing investors today.
  • Immunic believes that this data illustrates biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Immunic believes this data provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture.

Immunic Highlights 2023 Accomplishments and Upcoming Milestones

Retrieved on: 
Friday, January 5, 2024
Janus, Biotechnology, Conference, MRI, Serum, Histology, Regeneration, Entire, PMS, Multiple sclerosis, Woman, Disease, Sirtuin 6, Calcium, Clinical trial, Investment, AFL, SIRT6, Medicinal chemistry, Ulcerative colitis, Biomarker, Journal of Medicinal Chemistry, DHODH, Patient, Journal, RMS, Magnetic resonance imaging, Pharmaceutical industry

"With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.

Key Points: 
  • "With vidofludimus calcium (IMU-838) and IMU-856, we have two development programs beyond clinical proof-of-concept which is an outstanding achievement of our entire team.
  • A more thorough review of recent events and upcoming milestones follows:
    Announced a three-tranche private placement of up to $240 million with participation from select new and existing investors today.
  • Immunic believes that this data illustrates biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential.
  • Immunic believes this data provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture.

ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

Retrieved on: 
Tuesday, December 12, 2023
Liver, Atopic dermatitis, Eosinophilic bronchitis, Partnership, Dermatology, ASLN, Alopecia areata, Hair loss, Disease, MD, SAN, JAK, Beacon Grand Hotel, IGA, EASI, Institutional review board, TREK, DHODH, Patient, Safety, AA, Skin

SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.
  • “Throughout 2023, ASLAN made major progress on multiple fronts – advancing both of our lead programs, eblasakimab and farudodstat in Phase 2 testing, and establishing business development collaborations to further the development and utilization of eblasakimab,” said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals.
  • ASLAN will provide an update in early 2024 on the timing of the expected topline readout from the study in 2024.
  • Publication and presentation of further data from the TREK-AD study of eblasakimab, including biomarker data, and on farudodstat at major congresses.

ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata

Retrieved on: 
Thursday, May 18, 2023
Yale School of Medicine, 4,5-Dihydroorotic acid, Hair loss, ISID, ASLN, DHODH, Atopic dermatitis, Yale school, Associate, Psoriasis, Alopecia areata, Patient, International Society for Bipolar Disorders, SAN, Safety, Disease, Pharmaceutical industry, Dermatology, AA

The study, called “FAST-AA” (FArudodstat STudy in Alopecia Areata), will investigate farudodstat’s efficacy and safety in patients with at least 50% scalp hair loss.

Key Points: 
  • The study, called “FAST-AA” (FArudodstat STudy in Alopecia Areata), will investigate farudodstat’s efficacy and safety in patients with at least 50% scalp hair loss.
  • “We are excited to begin this trial investigating farudodstat in AA, a disease for which patients have very limited treatment options,” said Dr Alex Kaoukhov, Chief Medical Officer of ASLAN Pharmaceuticals.
  • “DHODH is an established target in the treatment of autoimmune diseases, and data from our recent studies support farudodstat’s potential to treat AA.
  • “Hence clinical development of novel therapies is crucial in AA and could significantly benefit patients.

EQS-News: Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Retrieved on: 
Wednesday, May 17, 2023
Neuroprotection, Sclerosis, Medicinal chemistry, GFAP, Glial fibrillary acidic protein, Ludwig Maximilian University of Munich, AFL, Biotechnology, Medication, DHODH, Journal of Medicinal Chemistry, Patent, Patient, Calcium, Frankincense, Pharmaceutical industry, Vaccine, Multiple sclerosis, Short course immune induction therapy

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Key Points: 
  • Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
    The issuer is solely responsible for the content of this announcement.
  • Activation of Nurr1 could be responsible for the drug’s postulated neuroprotective effects and may contribute to the previously reported reduction of confirmed disability worsening events in multiple sclerosis patients.
  • Specifically, preclinical data shows potent Nurr1 activation by vidofludimus calcium at low concentrations in several test systems.
  • In preclinical testing, we have discovered strong Nurr1 agonism by vidofludimus calcium,” stated Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic.

Syngenta and FMC to Commercialize Breakthrough Technology That Transforms Grass Weed Control in Rice in Asia

Retrieved on: 
Tuesday, May 16, 2023
Technology, Professional Services, Other Natural Resources, Environmental, Social and Governance (ESG), Agriculture, Natural Resources, Research, Environment, Science, Food Tech, Sustainability, Employment, HRAC, Farmer, DHODH, Light, Multimedia, Crop protection, Developed country, Herbicide, Water, FMC Corporation, FMC, Syngenta

Syngenta Crop Protection and FMC Corporation announced today an agreement to bring to market a breakthrough technology to control grass weeds in rice in Asia.

Key Points: 
  • Syngenta Crop Protection and FMC Corporation announced today an agreement to bring to market a breakthrough technology to control grass weeds in rice in Asia.
  • View the full release here: https://www.businesswire.com/news/home/20230516005103/en/
    Syngenta and FMC to bring to market breakthrough technology to control rice weeds in Asia.
  • Under the agreement, Syngenta and FMC will both bring Tetflupyrolimet based products to key rice markets in Asia.
  • In addition, Syngenta will commercialize products containing mixtures of Tetflupyrolimet for rice in India, Vietnam, Indonesia, as well as in Japan and South Korea.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting

Retrieved on: 
Monday, May 15, 2023
Learning, Hair, IL-12, ISID, ASLN, Research fellow, TARC, HF, DHODH, MHC, HFS, IP-10, Atopic dermatitis, Research, Inflammation, IP, Publication, Associate, Immune privilege, II, IL-2, Alopecia areata, Organization, Patient, International Society for Traumatic Stress Studies, SAN, Autoimmune disease, GM-CSF, Epithelium, MHC-II, Cytokine, AD, T helper cell, Johns Hopkins School of Medicine, Vaccine, Pharmaceutical industry, Dermatology, TH1, AA

“This late-breaking data offers new and important insights into the novel mechanisms of eblasakimab and farudodstat for atopic dermatitis (AD) and alopecia areata (AA) respectively," said Dr Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.

Key Points: 
  • “This late-breaking data offers new and important insights into the novel mechanisms of eblasakimab and farudodstat for atopic dermatitis (AD) and alopecia areata (AA) respectively," said Dr Ferda Cevikbas, Head of Translational Science at ASLAN Pharmaceuticals.
  • “Furthermore, data from an ex vivo human AA disease model demonstrates the potential for farudodstat to protect against immune privilege collapse in AA.
  • This study investigated whether farudodstat, a DHODH inhibitor, has potential in the treatment of AA using an innovative ex vivo model for AA.
  • Together, the findings highlight the potential for farudodstat as a novel therapy for AA.

EQS-News: Immunic to Participate in Investor and Scientific Conferences in May

Retrieved on: 
Wednesday, April 26, 2023
Inflammation, IST, Disease, Biotechnology, COVID-19, DHODH, Virology, Congress, Assistant professor, European, Psychiatry, Human, Poster, Therapy, Coeliac disease, Conference, Safety, Pharmaceutical industry, Neurology, Short course immune induction therapy

NEW YORK, April 26, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:

Key Points: 
  • NEW YORK, April 26, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
    May 2-4: Aegis Virtual Conference.
  • A webcast of the presentation will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .
  • An archived replay will be available on the company’s website for a period of 90 days after the conference.
  • Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present preclinical data on the antiviral properties of dihydroorotate dehydrogenase (DHODH) inhibitors in an oral presentation at this conference in Seattle, WA.

ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting

Retrieved on: 
Monday, April 24, 2023
Learning, Abstract, Neuron, Psoriasis Area and Severity Index, ASLN, Hair, DHODH, Head, Research, Neck, Immune privilege, MRGPRX2, Paul Khavari, Journal, Patient, International Society for Infectious Diseases, SAN, Interleukin, Drug development, Itch, Cytokine, AD, Pharmacology, Skin, JST, Medical imaging, Copper, Pharmaceutical industry, EASI, ISID

Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.

Key Points: 
  • Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.
  • “The abstracts published today highlight the potential of eblasakimab to offer important differentiated benefits for AD patients.
  • Spontaneous neuronal activity was not impacted by IL-13 treatment but was increased with IL-4 treatment, which was also effectively reduced by eblasakimab.
  • This indicates that direct impact on neuronal responses may contribute to reduction of chronic itch demonstrated in AD patients treated with eblasakimab.